Loading
Developed the anti-GD2 antibodies 3F8 and naxitamab that treat relapsed neuroblastoma.
Nai-Kong Cheung developed the murine anti-GD2 antibody 3F8 in the 1980s and its humanised successor naxitamab, which won FDA approval in 2020 for relapsed or refractory high-risk neuroblastoma in bone or bone marrow, and has led decades of MSKCC trials of antibody-based immunotherapy in children. His laboratory engineers bispecific antibodies and CAR T cells against GD2 and other paediatric targets.
| Title | Journal | Year |
|---|---|---|
| Naxitamab for high-risk neuroblastoma: a phase II trial | JCO | 2020 |
| Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission | JCO | 2012 |
Shares Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
Shares Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
Shares Neuroblastoma (paediatric) and the tags paediatric, neuroblastoma.
Shares the tags paediatric, immunotherapy.
Shares Naxitamab Study 201, Neuroblastoma (paediatric), Monoclonal antibodies.
Shares Neuroblastoma (paediatric) and the tag neuroblastoma.
Shares Neuroblastoma (paediatric) and the tag paediatric.